Article
Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
Pediatric blood & cancer - 1 Jun 2015
Dehury Snehadhini, Purohit Prasanta, Patel Siris, Meher Satyabrata, Kullu Bipin Kishore, Sahoo Lulup Kumar, Patel Nayan Kumar, Mohapatra Alok Kumar, Das Kishalaya, Patel Dilip Kumar
Abstract excerpt
BACKGROUND: Despite compelling evidence that hydroxyurea is safe and effective in sickle cell disease, it is prescribed sparingly due to several barriers like knowledge gaps in certain genotypes, apprehension about its safety and toxicity, and limited resources. We undertook this study to find out the efficacy and safety of HU in patients with HbSβ(+) -thalassemia with IVS1-5(G→C) mutation. PROCEDURE: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.